S1RP34 Stock Overview A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Sarepta Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sarepta Therapeutics Historical stock prices Current Share Price US$38.60 52 Week High US$45.78 52 Week Low US$28.23 Beta 0.76 1 Month Change 0.73% 3 Month Change 9.72% 1 Year Change 36.59% 3 Year Change 100.10% 5 Year Change n/a Change since IPO -5.62%
Recent News & Updates
Sarepta Therapeutics, Inc. Completes Enrollment in EMERGENE, Phase 3 Clinical Study of SRP-9003 for Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 Dec 18
Sarepta Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
Sarepta Therapeutics, Inc. Announces Appointment of Deirdre P. Connelly to Its Board of Directors Sep 16
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2025 Aug 08
Sarepta Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 29
Sarepta Therapeutics, Inc. Announces Expanded US FDA Approval of Eletidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above Jun 21 See more updates
Sarepta Therapeutics, Inc. Completes Enrollment in EMERGENE, Phase 3 Clinical Study of SRP-9003 for Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 Dec 18
Sarepta Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
Sarepta Therapeutics, Inc. Announces Appointment of Deirdre P. Connelly to Its Board of Directors Sep 16
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2025 Aug 08
Sarepta Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 29
Sarepta Therapeutics, Inc. Announces Expanded US FDA Approval of Eletidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above Jun 21 Sarepta Therapeutics, Inc., Annual General Meeting, Jun 06, 2024
Sarepta Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 22
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication Feb 16
Sarepta Therapeutics, Inc. Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 Jan 29
Sarepta Therapeutics, Inc. Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 Jan 16
Sarepta Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 26
Sarepta Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Sarepta Therapeutics, Inc. Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy May 13
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 Feb 18
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022 Jan 11
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022 Jan 10
Sarepta Therapeutics Announces That U.S. FDA Has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’S Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy Nov 29 Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023 Sarepta Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 28
Sarepta Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 27
Sarepta Therapeutics Submits Biologics License Application for Srp-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy Sep 30
Food and Drug Administration Lifts its Clinical Hold on Sarepta Therapeutics's SRP-5051 for the Treatment of Duchenne Muscular Dystrophy Sep 07
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 Aug 03
Sarepta Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 28
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies Jul 08
Sarepta Therapeutics, Inc. Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy Jun 24
Sarepta Therapeutics, Inc. Appoints Michael Chambers and Kathryn Boor to Its Board of Directors Jun 03
Sarepta Therapeutics, Inc., Annual General Meeting, Jun 02, 2022 Apr 26
Sarepta Therapeutics, Inc. Announces Not Stand for Re-Election of Mary Ann Gray as Board of Director Apr 07
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 Mar 03
Sarepta Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 24
Sarepta Therapeutics, Inc. Announces Topline Results from Part 2 of Study SRP-9001-102 Jan 12
Sarepta Therapeutics, Inc. to Initiate Part B of Momentum Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA Sep 29
Sarepta Therapeutics, Inc. Raises Product Revenue Guidance for Full Year of 2021 Aug 05
Sarepta Therapeutics, Inc. Announces Positive 12-Week Expression and Safety Results from the First 11 Participants Enrolled in Study SRP-9001-103 May 19
Sarepta Therapeutics, Inc. Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 May 04
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy May 01
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration Mar 19
Orsini Specialty Pharmacy Selected By Sarepta Therapeutics As A Limited Distribution Partner For AMONDYS 45 (casimersen) Mar 05
Sarepta Therapeutics, Inc. Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 Feb 26
Sarepta Therapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021 Feb 23
Sarepta Therapeutics, Inc. and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics Jan 14
Sarepta Therapeutics Announces Top-Line Results for Part 1 of Study SRP-9001-102 (Study 102) Jan 08
Sarepta Therapeutics, Inc. Announces Board and Management Changes Dec 16
Sarepta Therapeutics, Inc. Appoints Ian Estepan as Chief Financial Officer Dec 15
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM Dec 10
Sarepta Therapeutics, Inc. to Commence Dosing of the Next Study with Commercial Process Material for the Srp-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy Nov 07
Sarepta Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30 Shareholder Returns S1RP34 BR Biotechs BR Market 7D -1.3% 0.2% -0.08% 1Y 36.6% -4.9% -13.2%
See full shareholder returns
Return vs Industry: S1RP34 exceeded the BR Biotechs industry which returned -5.4% over the past year.
Return vs Market: S1RP34 exceeded the BR Market which returned -13.7% over the past year.
Price Volatility Is S1RP34's price volatile compared to industry and market? S1RP34 volatility S1RP34 Average Weekly Movement 8.2% Biotechs Industry Average Movement 9.0% Market Average Movement 5.1% 10% most volatile stocks in BR Market 9.9% 10% least volatile stocks in BR Market 3.1%
Stable Share Price: S1RP34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: S1RP34's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
Show more Sarepta Therapeutics, Inc. Fundamentals Summary How do Sarepta Therapeutics's earnings and revenue compare to its market cap? S1RP34 fundamental statistics Market cap R$72.80b Earnings (TTM ) R$735.48m Revenue (TTM ) R$9.90b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) S1RP34 income statement (TTM ) Revenue US$1.64b Cost of Revenue US$1.03b Gross Profit US$609.29m Other Expenses US$487.45m Earnings US$121.85m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 1.28 Gross Margin 37.14% Net Profit Margin 7.43% Debt/Equity Ratio 100.5%
How did S1RP34 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 20:43 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sarepta Therapeutics, Inc. is covered by 53 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Huidong Wang Barclays Zhiqiang Shu Berenberg
Show 50 more analysts 
